Metabolic Pathways and Targets in Chondrosarcoma

Authors

Ida Micaily, Thomas Jefferson UniversityFollow
Megan E Roche, Thomas Jefferson UniversityFollow
Mohammad Y Ibrahim, Seton Hall University
Ubaldo E. Martinez-Outshoorn, Thomas Jefferson UniversityFollow
Atrayee Basu Mallick, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

12-6-2021

Comments

This article is the author’s final published version in Frontiers in Oncology, Volume 11, December 2021, Article number 772263.

The published version is available at https://doi.org/10.3389/fonc.2021.772263. Copyright © Micaily et al.

Abstract

Chondrosarcomas are the second most common primary bone malignancy. Chondrosarcomas are characterized by the production of cartilaginous matrix and are generally resistant to radiation and chemotherapy and the outcomes are overall poor. Hence, there is strong interest in determining mechanisms of cancer aggressiveness and therapeutic resistance in chondrosarcomas. There are metabolic alterations in chondrosarcoma that are linked to the epigenetic state and tumor microenvironment that drive treatment resistance. This review focuses on metabolic changes in chondrosarcoma, and the relationship between signaling via isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), hedgehog, PI3K-mTOR-AKT, and SRC, as well as histone acetylation and angiogenesis. Also, potential treatment strategies targeting metabolism will be discussed including potential synergy with immunotherapies.

Recommended Citation

Micaily, Ida; Roche, Megan E; Ibrahim, Mohammad Y; Martinez-Outshoorn, Ubaldo E.; and Mallick, Atrayee Basu, "Metabolic Pathways and Targets in Chondrosarcoma" (2021). Department of Medical Oncology Faculty Papers. Paper 169.
https://jdc.jefferson.edu/medoncfp/169

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

34938658

Language

English